Inhibition of human breast cancer xenograft growth by cruciferous vegetable constituent benzyl isothiocyanate
Warin R, Xiao D, Arlotti JA, Bommareddy A, Singh SV
Molecular carcinogenesis · 56 citations
How it was studied
- Design
- Animal study (classified by our AI screen)
- Studied in
- People, plus animal or lab work
- Main outcome
- Clinical events such as disease or death
Who paid for it
- Funding
- Independent funding
- Government
- National Cancer Institute
- Government
- NCI NIH HHS
- Grants
- National Cancer Institute (R01 CA129347); National Cancer Institute (CA129347)
Based on 2 listed funder(s).
Publication
- Published
- 2010-04-21 · Mol Carcinog · vol. 49 · issue 5 · pp. 500–507
- Publisher
- Wiley
- Cited
- 77 citations · more than 90% of similar papers · 2.6× the field average
- Impact
- Top 10% most cited in its field
- References
- 36 works
- Access
- Open access (repository copy)
- Research areas
- Genomics, phytochemicals, and oxidative stress · Fungal Plant Pathogen Control · Glutathione Transferases and Polymorphisms
- Keywords
- Benzyl isothiocyanate, Angiogenesis, In vivo, Biology, Cancer research, Vascular endothelial growth factor, Cell growth, Terminal deoxynucleotidyl transferase, Neovascularization, Cancer, CD31, Apoptosis, Pharmacology, Endocrinology, TUNEL assay, Isothiocyanate, Biochemistry, VEGF receptors
- MeSH
- cell line, tumor, animals, humans, mice, mice, nude, vegetables, breast neoplasms, isothiocyanates, transplantation, heterologous, immunohistochemistry, in situ nick-end labeling, female
5 authors
From US
- Renaud WarinUniversity of Pittsburgh; UPMC Hillman Cancer Center
- Dong XiaoUPMC Hillman Cancer Center
- Julie A. ArlottiUPMC Hillman Cancer Center
- Ajay BommareddyUPMC Hillman Cancer Center
- Shivendra Vikram Singh · correspondingUPMC Hillman Cancer Center
Abstract
Benzyl isothiocyanate (BITC), a constituent of cruciferous vegetables such as garden cress, inhibits growth of human breast cancer cell lines in culture. The present study was undertaken to determine in vivo efficacy of BITC against MDA-MB-231 human breast cancer xenografts. The BITC administration retarded growth of MDA-MB-231 cells subcutaneously implanted in female nude mice without causing weight loss or any other side effects. The BITC-mediated suppression of MDA-MB-231 xenograft growth correlated with reduced cell proliferation as revealed by immunohistochemical analysis for Ki-67 expression. Analysis of the vasculature in the tumors from BITC-treated mice indicated smaller vessel area compared with control tumors based on immunohistochemistry for angiogenesis marker CD31. The BITC-mediated inhibition of angiogenesis in vivo correlated with downregulation of vascular endothelial growth factor (VEGF) receptor 2 protein levels in the tumor. Consistent with these results, BITC treatment suppressed VEGF secretion and VEGF receptor 2 protein levels in cultured MDA-MB-231 cells. Moreover, the BITC-treated MDA-MB-231 cells exhibited reduced capacity for migration compared with vehicle-treated control cells. In contrast to cellular data, BITC administration failed to elicit apoptotic response as judged by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay. In conclusion, the present study demonstrates in vivo anti-cancer efficacy of BITC against MDA-MB-231 xenografts in association with reduced cell proliferation and suppression of neovascularization. These preclinical observations merit clinical investigation to determine efficacy of BITC against human breast cancers.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.